[go: up one dir, main page]

AU2003241279A8 - Antimicrobial polymer conjugates - Google Patents

Antimicrobial polymer conjugates

Info

Publication number
AU2003241279A8
AU2003241279A8 AU2003241279A AU2003241279A AU2003241279A8 AU 2003241279 A8 AU2003241279 A8 AU 2003241279A8 AU 2003241279 A AU2003241279 A AU 2003241279A AU 2003241279 A AU2003241279 A AU 2003241279A AU 2003241279 A8 AU2003241279 A8 AU 2003241279A8
Authority
AU
Australia
Prior art keywords
polymer conjugates
antimicrobial polymer
antimicrobial
conjugates
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003241279A
Other versions
AU2003241279A1 (en
Inventor
Andrew Lees
Anjali Shah
Joseph Drabick
Scott Walsh
James Mond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosynexus Inc
Original Assignee
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosynexus Inc filed Critical Biosynexus Inc
Publication of AU2003241279A8 publication Critical patent/AU2003241279A8/en
Publication of AU2003241279A1 publication Critical patent/AU2003241279A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003241279A 2002-03-26 2003-03-26 Antimicrobial polymer conjugates Abandoned AU2003241279A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36811202P 2002-03-26 2002-03-26
US60/368,112 2002-03-26
PCT/US2003/009279 WO2003082926A2 (en) 2002-03-26 2003-03-26 Antimicrobial polymer conjugates

Publications (2)

Publication Number Publication Date
AU2003241279A8 true AU2003241279A8 (en) 2003-10-13
AU2003241279A1 AU2003241279A1 (en) 2003-10-13

Family

ID=28675445

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003241279A Abandoned AU2003241279A1 (en) 2002-03-26 2003-03-26 Antimicrobial polymer conjugates

Country Status (8)

Country Link
US (2) US7452533B2 (en)
EP (1) EP1494706A4 (en)
JP (1) JP2005528372A (en)
CN (1) CN1655812A (en)
AU (1) AU2003241279A1 (en)
BR (1) BR0308710A (en)
CA (1) CA2479807A1 (en)
WO (1) WO2003082926A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476288A1 (en) * 2002-03-26 2003-10-09 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
EP1494706A4 (en) * 2002-03-26 2006-10-25 Biosynexus Inc Antimicrobial polymer conjugates
SE526027C2 (en) * 2003-05-23 2005-06-14 Gambro Lundia Ab Biocompatible polymer composition with antibacterial properties, useful e.g., in medical devices, wound dressings, and food and medicine storage containers, comprises a bismuth complex such as triphenylbismuth dichloride
WO2005072778A2 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
WO2006110776A2 (en) 2005-04-12 2006-10-19 Nektar Therapeutics Al, Corporation Polyethylene glycol cojugates of antimicrobial agents
JP2009526069A (en) * 2006-02-08 2009-07-16 バイオシネクサス インコーポレーティッド Neutralization of bacterial spores
WO2008105826A2 (en) * 2006-09-05 2008-09-04 Biosynexus Incorporated Compositions compromising lysostaphin variants and methods of using the same
TWI412591B (en) * 2007-04-20 2013-10-21 Sigma Tau Rare Diseases S A Stable recombinant adenosine deaminase
CA2696996C (en) * 2007-07-16 2016-03-22 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Antimicrobial constructs
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
KR101635795B1 (en) 2009-12-17 2016-07-04 피나 바이오솔루션스, 엘엘씨 Activation of Polysaccharides via the Cyanylating Agent, 1-cyanobenzotriazole (1-CBT) in the Preparation of Polysaccharide/Protein Conjugate Vaccines
EP2560738B8 (en) 2010-04-23 2019-09-25 Serum Institute of India Private Limited Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
US9814766B2 (en) 2013-12-28 2017-11-14 Longhorn Vaccines And Diagnostics, Llc Multimodal antimicrobial therapy
CN114099640A (en) * 2021-12-14 2022-03-01 立康荣健(北京)生物医药科技有限公司 Antibacterial peptide composition for inhibiting and killing Helicobacter pylori, preparation method and application thereof
CN116076506B (en) * 2022-12-26 2025-04-04 中粮营养健康研究院有限公司 Biological antibacterial agents and their applications

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433883C2 (en) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Use of physiologically active polypeptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1578348A (en) 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4931390A (en) * 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5858962A (en) 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
DE3739347A1 (en) * 1987-11-20 1989-06-01 Hoechst Ag METHOD FOR SELECTIVE CLEAVAGE OF FUSION PROTEINS
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
AU5858690A (en) * 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
JPH0369665A (en) * 1989-08-04 1991-03-26 Unitika Ltd Production of antimicrobial fiber structure
JPH03213516A (en) * 1990-01-16 1991-09-18 Kanebo Ltd Production of antimicrobial conjugate fiber
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5783178A (en) * 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
EP0921817B1 (en) * 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
US6028051A (en) 1997-07-23 2000-02-22 Ambi Inc. Method for the treatment of staphylococcal disease
JPH1161569A (en) * 1997-08-19 1999-03-05 Unitika Ltd Antimicrobial conjugate yarn
US6875903B2 (en) * 1998-06-22 2005-04-05 University Of Vermont Treatment of Staphylococcus infections
US6565854B2 (en) * 1998-08-13 2003-05-20 Philadelphia Health And Education Corporation Antimicrobial histone H1 compositions, kits, and methods of use thereof
US6315996B1 (en) * 1999-04-09 2001-11-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Topical lysostaphin therapy for staphylococcus ocular infections
WO2001004287A1 (en) 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
US6056955A (en) * 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US6379654B1 (en) * 2000-10-27 2002-04-30 Colgate Palmolive Company Oral composition providing enhanced tooth stain removal
CA2476288A1 (en) * 2002-03-26 2003-10-09 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
EP1494706A4 (en) * 2002-03-26 2006-10-25 Biosynexus Inc Antimicrobial polymer conjugates

Also Published As

Publication number Publication date
JP2005528372A (en) 2005-09-22
CA2479807A1 (en) 2003-10-09
AU2003241279A1 (en) 2003-10-13
US7452533B2 (en) 2008-11-18
US20090081180A1 (en) 2009-03-26
US20030215436A1 (en) 2003-11-20
WO2003082926A9 (en) 2004-05-27
BR0308710A (en) 2007-01-09
EP1494706A4 (en) 2006-10-25
EP1494706A2 (en) 2005-01-12
WO2003082926A3 (en) 2004-04-01
WO2003082926A2 (en) 2003-10-09
CN1655812A (en) 2005-08-17

Similar Documents

Publication Publication Date Title
AU2002367577A8 (en) Antimicrobial polymer
AU2003207801A1 (en) Antimicrobial polymer
GB0222522D0 (en) Water-swellable polymers
IL156168A (en) Polymeric agricultural articles
TWI319767B (en) Dendrimer
AU2003278857A8 (en) Oligonucleotide conjugates
AU2003241279A8 (en) Antimicrobial polymer conjugates
EP1482957A4 (en) Antibiotic conjugates
DE60333033D1 (en) Pulverförmiges thermoplastisches polymer
GB2418921B (en) Antimicrobial polymers
AU2003267540A8 (en) Biodegradable polymer
GB2393446B (en) Polymer
EP1657978A4 (en) Antimicrobial acrylic polymer
AU2003241920A1 (en) Antimicrobial envelopes
GB2398790B (en) Polymer compositions
GB0207013D0 (en) Polymer composition
GB0310858D0 (en) Polymer transistor
AU2003235768A8 (en) Molecular trichogram
AU2003292197A8 (en) Lna-cpg conjugates
GB0310335D0 (en) Biodegradable polymer
GB0200505D0 (en) Highly functional polymers
GB0201593D0 (en) Ferromagnetic polymer
AU2003201672A1 (en) Polymer conjugates
AU2002953173A0 (en) Antimicrobial polymers
AU2003906771A0 (en) Antimicrobial polymers

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase